Waldenstrom macroglobulinemia cells devoid of BTK(C481S) or CXCR4(WHIM-like) mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment

Although ibrutinib is highly effective in Waldenstrom macroglobulinemia (WM), no complete remissions in WM patients treated with ibrutinib have been reported to date. Moreover, ibrutinib-resistant disease is being steadily reported and is associated with dismal clinical outcome (overall survival of...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Blood Cancer J
Κύριοι συγγραφείς: Paulus, A, Akhtar, S, Yousaf, H, Manna, A, Paulus, S M, Bashir, Y, Caulfield, T R, Kuranz-Blake, M, Chitta, K, Wang, X, Asmann, Y, Hudec, R, Springer, W, Ailawadhi, S, Chanan-Khan, A
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Nature Publishing Group 2017
Θέματα:
Original Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5518884/
https://ncbi.nlm.nih.gov/pubmed/28548645
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bcj.2017.40
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια